Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“As a condition to closing our US venture round led by Sequoia Capital, we needed to complete a complex corporate restructuring to flip our foreign domiciled company to become a US based HQ (we had been operating as a South African based entity for several years). We needed a CFO to lead that project, hire and train global finance, legal and HR teams, and help us to expand our multinational footprint.
I hired Mary Korn for her breadth of experience and her ability to work across time zones to remotely manage a team around the globe. Working closely with legal and SA regulators, she completed the restructuring, implemented a sustainable budget program, hired and coached an outstanding team for our G&A organization, and raised a round of capital to support our expansion across sub-Saharan Africa. Our growing business needed horsepower in the team and the addition of Mary was a boost for us. Mary was also one of the best mentor’s we ever had in the company and not only did she build a great team around her she invested in mentoring me personally.”
Pieter de Villiers, CEO and Co-Founder, Clickatell Read More
